الفهرس | Only 14 pages are availabe for public view |
Abstract The aim of this work is to formulate Paclitaxel (PTX) into two different lipid nanoparticles with solid matrix: Solid Lipid Nanoparticles (SLN) and the improved form Nanostructured Lipid Carriers (NLC). This may lead to increase in efficacy, prolong the action and minimize the adverse effects of paclitaxel by increasing its cytotoxic efficacy which leads to decreased drug dosage in addition to the avoidance of chremophore El – accompanied allergic reactions. For both SLN and NLC, 23 full factorial design was constructed and eight formulae of each system were prepared. Three independent variables was selected for each system, For NLCs, the variables are: type of liquid lipid, type and concentration of surfactant. For SLNs, due to absence of liquid lipid, this variable was replaced by the concentration of drug entrapped. All formulae were prepared by Homogenization – Ultrasonication technique. The thesis is divided into five chapters: chapter one contains the preformulation studies for PTX and the used excipients. Chapter two reviews the prepared PTX-NLCs formulae. In this chapter, morphology, particle size, and zeta potential are evaluated for characterization of the matrix system. Entrapment efficiency, drug loading and in vitro release were evaluated. Chapter three reviews PTX-SLNs formulae, same studies was done as in chapter two. In chapter four the best NLC and SLN formulae were selected. The in vitro cytotoxicity study was done for the selected formulae using MCF-7 cell line. In chapter five a stability study was done for 6 months at 25° C. Results showed that PTX formulated into both lipid matrix formulae prolonged PTX release and increased the in vitro cytotoxicity. PTX-NLC had higher entrapment efficiency than PTX-SLN. Both PTX-NLC and PTX-SLN are considered efficient carriers for PTX delivery; they increase its in vitro cytotoxicity and decreased its side effects. |